GlassScriptPhysician profile
Michiko K Bruno
NPI 1073618377
$3,466.18
in general payments reported to CMS, 2019-2025
27 companies · $385 in 2025
The $385 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,355 · 2020: $259 · 2021: $48.93 · 2022: $177 · 2023: $497 · 2024: $744 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,527 · Education: $99.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,526.52 |
| Education | $99.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $1,073.40 | 2019-2020 | |
| Insightec,INC | $427.73 | 2022-2025 | Exablate |
| Pfizer INC. | $264.56 | 2023-2025 | |
| Abbvie INC. | $254.76 | 2019-2025 | Duopa, Botox |
| Medtronic, INC. | $193.92 | 2022-2025 | Percept PC Brainsense, Activa PC |
| Eisai INC. | $189.32 | 2023-2024 | |
| Abbott Laboratories | $183.38 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $121.74 | 2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $119.51 | 2019 | |
| Siemens Medical Solutions USA, INC. | $93.15 | 2023 | |
| Amgen INC. | $57.76 | 2019-2024 | Uplizna |
| Boston Scientific Corporation | $52.69 | 2025 | General - Dbs |
| Allergan, INC. | $48.76 | 2019 | |
| Ucb, INC. | $48.64 | 2019 | |
| Genentech USA, INC. | $47.72 | 2024 | Ocrevus Zunovo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainlab, INC. | $47.46 | 2024 | Surgical Planning and Navigation Radiation Treatment Planning and Positioning |
| Acadia Pharmaceuticals INC | $35.07 | 2019 | |
| Alexion Pharmaceuticals, INC. | $30.30 | 2025 | Ultomiris |
| Merz North America, INC. | $26.42 | 2019 | |
| Amneal Pharmaceuticals LLC | $24.19 | 2024 | Rytary |
| Cycle Pharmaceuticals INC | $22.79 | 2025 | Bafiertam |
| Horizon Therapeutics Plc | $20.35 | 2023 | Uplizna |
| Novartis Pharmaceuticals Corporation | $18.71 | 2019 | |
| Ge Healthcare | $18.26 | 2025 | |
| Lundbeck LLC | $17.05 | 2019 | |
| Lilly USA, LLC | $15.97 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michiko Bruno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.